References
- Beuselinck B, Vano YA, Oudard S, et al (2014). Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int, 114, 81-9. https://doi.org/10.1111/bju.12494
- Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75. https://doi.org/10.7314/APJCP.2014.15.8.3369
- Edesa WA, Abdelmalek RR (2015). Efficacy and toxicity of sunitinib in egyptian patients with metastatic renal cell carcinoma. Asian Pac J Cancer Prev, 16, 1971-76. https://doi.org/10.7314/APJCP.2015.16.5.1971
- Fujita T, Iwamura M, Ishii D, et al (2012). C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol, 19, 908-13. https://doi.org/10.1111/j.1442-2042.2012.03071.x
- Gore ME, Szczylik C, Porta C, et al (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol, 10, 757-63. https://doi.org/10.1016/S1470-2045(09)70162-7
- Gore ME, Hariharan S, Porta C, et al (2011), Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 117, 501-9. https://doi.org/10.1002/cncr.25452
- Kawai Y, Osawa T, Kobayashi K, et al (2015). Factors prognostic for survival in Japanese patients treated with sunitinib as first-line therapy for metastatic clear cell renal cell cancer. Asian Pac J Cancer Prev, 16, 5687-90. https://doi.org/10.7314/APJCP.2015.16.14.5687
- Kim HS, Hong MH, Kim K, et al (2011). Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles. Oncol, 80, 395-405. https://doi.org/10.1159/000330361
- Krishna VM, Noronha V, Prabhash K, et al (2013). Sunitinib in metastatic renal cell carcinoma: A single center experience. Indian J Cancer, 50, 268-73. https://doi.org/10.4103/0019-509X.118725
- Miyake H, Harada K, Miyazaki A, Fujisawa M (2015). Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol, 32, 78. https://doi.org/10.1007/s12032-015-0528-8
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17, 2530-40. https://doi.org/10.1200/JCO.1999.17.8.2530
- Motzer RJ, Bukowski RM (2006). Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol, 24, 5601-08. https://doi.org/10.1200/JCO.2006.08.5415
- Motzer RJ, Hutson TE, Tomczak P, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, 115-24. https://doi.org/10.1056/NEJMoa065044
- Motzer RJ, Hutson TE, Tomczak P, et al (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 27, 3584-90. https://doi.org/10.1200/JCO.2008.20.1293
- Najjar YG, Mittal K, Elson P, et al (2014). A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer, 50, 1084-9. https://doi.org/10.1016/j.ejca.2014.01.025
- Negrier S, Escudier B, Lasset C, et al (1998). Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med, 338, 1272-78. https://doi.org/10.1056/NEJM199804303381805
- Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003). Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res, 9, 4641-52.
- Pantuck AJ, Seligson DB, Klatte T, et al (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 109, 2257-67. https://doi.org/10.1002/cncr.22677
- Powles T, Chowdhury S, Jones R, et al (2011). Sunitinib and other targeted therapies for renal cell carcinoma. Brit J Cancer, 104, 741-45. https://doi.org/10.1038/sj.bjc.6606061
- Schnadig IA, Hutson TE, Chung H, et al (2014). Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in communitybased practices. Clinical Genitourinary Cancer, 12, 413-21. https://doi.org/10.1016/j.clgc.2014.06.015
- Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
- Wagstaff J, Jones R, Hawkins R, et al (2016). Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol, 27, 159-65. https://doi.org/10.1093/annonc/mdv504